https://mindmedicinelaw.com/briefing/ketamine-use-surge-in-uk-raises-health-concerns-20260708-20106The Psychedelic Journalen2026-07-08T22:04:14.381200+00:00Ketamine Use Surge in UK Raises Health Concernsketamine use, public health, harm reduction, UK drug policy, ketamine bladder syndrome, NMDA receptors, drug misuse, therapeutic ketamine, pain management, regulatory approacheshttps://mindmedicinelaw.com/briefing/fda-targets-illegal-ketamine-sellers-amid-psychedelic-growth-20260708-20262The Psychedelic Journalen2026-07-08T22:04:03.748584+00:00FDA Targets Illegal Ketamine Sellers Amid Psychedelic GrowthFDA, ketamine, psychedelic regulation, illegal sales, mental health, compliance, clinical trials, market expansion, public health, therapeutic potentialhttps://mindmedicinelaw.com/briefing/dea-s-proposed-schedule-i-classification-for-tianeptine-20260708-19964The Psychedelic Journalen2026-07-08T15:04:35.578599+00:00DEA's Proposed Schedule I Classification for Tianeptinetianeptine, DEA, Schedule I, controlled substances, drug regulation, research restrictions, market impact, substance abuse, psychedelic research, legal implicationshttps://mindmedicinelaw.com/briefing/gut-microbiota-and-cognitive-impairment-in-mdd-new-insights-from-china-20260707-20042The Psychedelic Journalen2026-07-08T22:04:41.128967+00:00Gut Microbiota and Cognitive Impairment in MDD: New Insights from Chinagut microbiota, oxidative stress, cognitive impairment, major depressive disorder, mental health research, therapeutic strategies, China pilot study, inflammation, psychobiotics, brain-gut axishttps://mindmedicinelaw.com/briefing/2-adrenergic-receptor-s-impact-on-mdma-psilocybin-effects-20260707-20102The Psychedelic Journalen2026-07-08T22:04:31.948415+00:00α(2)-Adrenergic Receptor's Impact on MDMA, Psilocybin Effectsα(2)-adrenergic receptor, 5-HT(2A) receptor, MDMA effects, psilocybin effects, psychedelic therapy, receptor interactions, clinical trials, neuroscience, safety profiles, therapeutic strategieshttps://mindmedicinelaw.com/briefing/biopsychosocial-insights-into-stress-induced-psychopathology-20260707-20015The Psychedelic Journalen2026-07-08T22:04:22.039730+00:00Biopsychosocial Insights into Stress-Induced Psychopathologystress-induced psychopathology, biopsychosocial model, anxiety disorders, neurobiological factors, genetic influences, personalized interventions, PTSD symptom fluctuation, bioenergetic signatures, complex systems, psychiatric disordershttps://mindmedicinelaw.com/briefing/2-adrenergic-receptor-s-role-in-modulating-mdma-psilocybin-effects-20260707-19995The Psychedelic Journalen2026-07-08T15:05:05.916386+00:00α2-Adrenergic Receptor's Role in Modulating MDMA, Psilocybin Effectsα2-adrenergic receptors, MDMA effects, psilocybin modulation, psychedelic therapies, serotonin receptors, norepinephrine, clinical trials, receptor interactions, therapeutic development, side effects reductionhttps://mindmedicinelaw.com/briefing/ayahuasca-s-potential-in-depression-research-implications-and-challenges-20260707-20075The Psychedelic Journalen2026-07-08T15:04:54.322075+00:00Ayahuasca's Potential in Depression Research: Implications and Challengesayahuasca, depression research, treatment-resistant depression, clinical trials, serotonin receptors, pharmacological profile, psychedelic therapy, DMT, mental health, regulatory frameworkshttps://mindmedicinelaw.com/briefing/ketamine-s-cognitive-effects-in-trd-new-findings-20260707-20043The Psychedelic Journalen2026-07-08T15:04:45.609350+00:00Ketamine's Cognitive Effects in TRD: New Findingsketamine, treatment-resistant depression, cognitive function, personalized treatment, clinical trials, mental healthhttps://mindmedicinelaw.com/briefing/psychedelic-treatment-for-postpartum-depression-new-horizons-20260707-19950The Psychedelic Journalen2026-07-07T22:05:06.034539+00:00Psychedelic Treatment for Postpartum Depression: New Horizonspsychedelic treatment, postpartum depression, mental health, clinical trials, neuroscience, public health, serotonin pathways, FDA regulations, neuroplasticity, emotional processinghttps://mindmedicinelaw.com/briefing/compass-pathways-psilocybin-phase-iii-trial-durable-effects-20260707-19791The Psychedelic Journalen2026-07-07T15:04:37.729192+00:00Compass Pathways' Psilocybin Phase III Trial: Durable Effectspsilocybin therapy, Compass Pathways, Phase III trial, psychedelic research, mental health treatment, neuroplasticity, regulatory approval, long-term efficacy, serotonin receptors, clinical safetyhttps://mindmedicinelaw.com/briefing/biomarker-guided-antidepressant-trial-for-mdd-insights-implications-20260706-20044The Psychedelic Journalen2026-07-08T22:04:58.147974+00:00Biomarker-Guided Antidepressant Trial for MDD: Insights & Implicationsbiomarker-guided treatment, major depressive disorder, bupropion, sertraline, precision medicine, clinical trial, antidepressant response, personalized treatment, biobehavioral markers, mental health researchhttps://mindmedicinelaw.com/briefing/psilocibin-safety-review-multi-organ-effects-under-scrutiny-20260706-20032The Psychedelic Journalen2026-07-08T15:05:24.199019+00:00Psilocibin Safety Review: Multi-Organ Effects Under Scrutinypsilocibin safety, multi-organ effects, serotonergic hallucinogen, treatment-resistant depression, clinical trials, psychedelic research, biologically plausible mechanisms, safety signals, therapeutic applications, regulatory guidelineshttps://mindmedicinelaw.com/briefing/depression-in-neurodegenerative-diseases-new-treatment-insights-20260706-19997The Psychedelic Journalen2026-07-08T15:05:15.035612+00:00Depression in Neurodegenerative Diseases: New Treatment Insightsdepression, neurodegenerative diseases, Alzheimer's disease, Parkinson's disease, emerging therapies, neurobiological mechanisms, clinical trials, precision psychiatry, treatment resistance, brain stimulationhttps://mindmedicinelaw.com/briefing/tfus-in-schizophrenia-evidence-mechanisms-and-future-directions-20260706-19872The Psychedelic Journalen2026-07-07T22:05:15.773514+00:00tFUS in Schizophrenia: Evidence, Mechanisms, and Future Directionstranscranial focused ultrasound stimulation, tFUS, schizophrenia treatment, neuromodulation, clinical trials, non-invasive therapy, brain networks, neuroscience researchhttps://mindmedicinelaw.com/briefing/ketamine-s-eeg-effects-vary-in-tr-mdd-tr-ptsd-tr-ocd-20260706-19884The Psychedelic Journalen2026-07-07T22:04:31.140623+00:00Ketamine's EEG Effects Vary in TR-MDD, TR-PTSD, TR-OCDketamine, EEG, treatment-resistant depression, post-traumatic stress disorder, obsessive-compulsive disorder, personalized psychiatry, psychedelic therapy, neural mechanisms, clinical trials, psychiatric carehttps://mindmedicinelaw.com/briefing/subcutaneous-ketamine-for-trd-kads-study-extension-insights-20260706-19885The Psychedelic Journalen2026-07-07T22:04:16.584922+00:00Subcutaneous Ketamine for TRD: KADS Study Extension Insightssubcutaneous ketamine, treatment-resistant depression, KADS study, clinical trials, depression treatment, psychedelic research, mental health, long-term effects, safety profile, antidepressant therapyhttps://mindmedicinelaw.com/briefing/psilocybin-mdma-efficacy-for-ptsd-trd-in-systematic-review-20260705-19840The Psychedelic Journalen2026-07-07T22:04:40.723595+00:00Psilocybin & MDMA: Efficacy for PTSD & TRD in Systematic Reviewpsilocybin, MDMA, PTSD, treatment-resistant depression, systematic review, clinical trials, psychedelic therapy, mental health, Phase 3 trials, regulatory implicationshttps://mindmedicinelaw.com/briefing/ayahuasca-s-potential-in-reducing-alcohol-relapse-preclinical-insights-20260704-19458The Psychedelic Journalen2026-07-07T15:05:26.450292+00:00Ayahuasca's Potential in Reducing Alcohol Relapse: Preclinical Insightsayahuasca, alcohol relapse, preclinical research, neurochemistry, oxidative stress, psychedelic-assisted therapy, alcohol use disorder, clinical trials, psychedelic research, addiction treatmenthttps://mindmedicinelaw.com/briefing/proposed-framework-for-ibogaine-medical-development-20260703-19462The Psychedelic Journalen2026-07-07T15:05:36.950183+00:00Proposed Framework for Ibogaine Medical Developmentibogaine development, psychoactive substances, clinical trials, safety and efficacy, regulatory pathways, neurotransmitter systems, addiction treatment, psychopharmacology, cardiac toxicity, psychedelic medicinehttps://mindmedicinelaw.com/briefing/oregon-s-regulatory-merger-psilocybin-and-marijuana-oversight-20260703-19794The Psychedelic Journalen2026-07-07T15:04:50.723486+00:00Oregon's Regulatory Merger: Psilocybin and Marijuana Oversightoregon psilocybin regulation, marijuana oversight merger, regulatory consolidation, psilocybin fee hike, oregon health authority, psychedelic industry policy, business compliance costs, clinical trial implications, public perception of psychedelics, state regulatory frameworkshttps://mindmedicinelaw.com/briefing/psilocybin-s-potential-for-treating-eating-disorders-20260702-19787The Psychedelic Journalen2026-07-07T15:04:59.733016+00:00Psilocybin's Potential for Treating Eating Disorderspsilocybin, eating disorders, transdiagnostic treatment, clinical guidelines, mental health, psychedelic research, serotonin modulation, treatment protocols, psychopathology, clinical trialshttps://mindmedicinelaw.com/briefing/mdma-assisted-therapy-for-ptsd-aud-new-clinical-trial-20260701-19858The Psychedelic Journalen2026-07-07T22:04:53.768037+00:00MDMA-Assisted Therapy for PTSD & AUD: New Clinical TrialMDMA-assisted therapy, PTSD treatment, alcohol use disorder, clinical trial, integrated exposure therapy, mental health researchhttps://mindmedicinelaw.com/briefing/psilocybin-s-impact-on-brain-circuits-long-term-effects-modeled-20260701-19788The Psychedelic Journalen2026-07-07T15:05:08.928913+00:00Psilocybin's Impact on Brain Circuits: Long-Term Effects Modeledpsilocybin, brain circuits, fronto-striatal-thalamic connectivity, neuropsychiatric disorders, clinical trials, therapeutic applications, neuroscience, psychedelic research, long-term effects, mental health